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Abstract
Background—Adiponectin is a protein derived from adipose tissue suspected to play an 
important role in prostate carcinogenesis. Variants in the adiponectin gene (ADIPOQ) and its type 
I receptor (ADIPOR1) have been recently linked to risk of both breast and colorectal cancer. 
Therefore, we set out to examine the relationship between polymorphisms in these genes, obesity 
and prostate cancer in study of African American men.
Methods—Ten single nucleotide polymorphisms (SNPs) in ADIPOQ and ADIPOR1 were 
genotyped in DNA samples from 131 African American prostate cancer cases and 344 controls 
participating in the Flint Men's Health Study. Logistic regression was then used to estimate their 
association with prostate cancer and obesity.
Results—While no significant associations were detected between any of the tested SNPs and 
prostate cancer, the rs1501299 SNP in ADIPOQ was significantly associated with body mass 
(p=0.03).
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms




Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2011 June 01.
Published in final edited form as:













Conclusions—Genetic variation in ADIPOQ and ADIPOR1 did not predict risk of prostate 
cancer in this study of African American men. However, the rs1501299 SNP in ADIPOQ was 
associated with obesity. Further investigation is warranted to determine if racial differences exist 
in the influence of the adiponectin pathway on prostate cancer risk.
Keywords
adipokines; body mass index; genetic susceptibility; single nucleotide polymorphism; racial 
differences
Introduction
Obese men diagnosed with prostate cancer have been shown to possess more aggressive 
tumor characteristics, an increased risk for biochemical recurrence and death(1-3). While the 
mechanism remains unclear, the poorer prognosis observed among obese patients suggests 
an etiologic heterogeneity driven by androgens, insulin resistance and/or chronic 
inflammation(4). However, alternative explanations include delayed detection of disease due 
to false negative prostate specific antigen (PSA) test results(5;6). It has been suggested that 
PSA hemodilution is the underlying cause of the observed inverse relationship between 
body mass and PSA concentration(7).
Adiponectin, one of a number of cytokines produced almost exclusively by adipocytes, has 
been hypothesized as a link between obesity and advanced prostate cancer. An inverse 
relationship between serum adiponectin concentrations and prostate cancer risk has been 
demonstrated in a number of studies(8-10), however no study to our knowledge has been 
able to recruit an adequate number of African Americans to explore the role of adipokines 
and prostate cancer in this high-risk group of men.
It has been estimated that a significant proportion (30% to 70%) of the variability in 
circulating plasma adiponectin is influenced by genetics(11). Several variants of the 
adiponectin (ADIPOQ)(12) and receptor 1 (ADIPOR1)(13) genes have been associated with 
obesity(14;15) cardiovascular disease(16), diabetes(14;17) and more recently cancers of the 
breast and colorectum (18;19). And again, a vast majority of these studies have been 
conducted in either largely or exclusively Caucasian populations. The relationship between 
these genes and prostate cancer has not been adequately explored. Therefore, we aimed to 
examine the association between several variants in ADIPOQ and ADIPOR1 with both 
obesity and prostate cancer risk using samples collected from an established case-control 
study of prostate cancer in African American men.
Materials and Methods
The Flint Men's Health Study (FMHS) is a community-based study of prostate cancer in 
African-Americans between the ages of 40-79. In 1996, 730 men were recruited to 
participate in the study from a probability sample residing in the city of Flint, Michigan and 
surrounding communities. Subjects completed a detailed in-home interview, and 379 of 
these men also participated in a clinical and urologic examination which included 
measurement of serum PSA. Men with an elevated total PSA (≥4.0 ng/mL) or an abnormal 
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digital rectal exam were referred for prostate biopsy. Twenty-eight subjects were diagnosed 
with prostate cancer as a consequence of the initial protocol or during follow-up, resulting in 
a final sample of 351 controls. A sufficient DNA sample was available for genotyping on 
344 of remaining controls.
Prostate cancer cases aged 40 to 79 years and diagnosed between January 1, 1995 and 
December 31, 2002 were recruited from the same community through the Genesee County 
Community-Wide Hospital Oncology Program (CHOP) registry. All cases completed a 
detailed epidemiologic interview and provided a blood sample for DNA analysis. Medical 
records were reviewed to collect clinical and pathologic stage, Gleason grade, pre-diagnostic 
PSA and primary treatment. A total of 136 cases were ultimately recruited to participate in 
the study, with DNA available on 131 for this investigation. Height and weight were 
measured by trained health professionals. Informed consent was obtained from all study 
participants and the research protocol has been approved by the Institutional Review Board 
of the University of Michigan. For both cases and controls, genomic DNA was isolated from 
whole blood using the Puregene DNA Purification Kit (Gentra Systems, Minneapolis, MN).
SNP Selection and Genotyping Methods
Ten single nucleotide polymorphisms in ADIPOQ and ADIPOR1 were selected in an effort 
to compare results in this investigation with the findings in breast and colorectal cancer 
(ADIPOQ) -11365 C>G (rs266729), -4034 A>C (rs822395), -3964 A>G (rs822396), +45 
T>G (rs2241766), +276 G>T (rs1501299), (ADIPOR1) -11760 G>A (rs2232853), -1742 
C>T (rs12733285), +5843 C>T (rs1342387), +10225 G>C (rs7539542), +11363 A>C 
(rs10920531). The SNPs were originally selected based their ability to tag the major 
haplotype blocks in each gene among samples in their study, a minor allele frequency of 
greater than 10%, with preferential selection given to SNPs with functional 
relevance(18;19).
Genotyping for all SNPs was performed using TaqMan SNP Genotyping Assays (Applied 
Biosystems, Foster City, CA). Genotyping reactions include 2.5 μL of TaqMan master mix, 
0.25 μL of Assay SNP Genotyping Assay pre-mix of primers and probes, and 2.25 μL of 5 
ng/μL template DNA. All PCR was conducted in a 384-well plate format and subjected to a 
universal PCR protocol of 95°C for 10 minutes, followed by 40 cycles of denaturation at 
92°C for 15 seconds followed by an annealing extension step of 60°C for 1 minute. 
Reactions were analyzed using the ABI PRISM 7900 HT Sequence Detection System and 
the SDS Version 2.1 software (Applied Biosystems). We achieved an average genotyping 
call rate of 95.5%, with call rates ≥ 93.1% for each SNP with one exception (rs12733285 
(82%)). All samples not genotyped using this method were directly sequenced using primers 
purchased from Invitrogen Life Technologies (primer sequences available upon request). 
Each PCR reaction included 5 μL of 10× PCR buffer (Invitrogen), 1.5 μL of 50mM MgCl, 5 
μL of forward primer at 5mM concentration, 5 μL of reverse primer at 5mM concentration, 1 
μL 10 mM dNTPs, 29 μL water, 0.5 μL Platinum Taq DNA polymerase (Invitrogen), and 60 
ng of genomic DNA. PCR products were then cleaned using Montage PCR Centrifugal 
Filter Devices (Millipore, Billerica, MA) and sequenced on an ABI Prism 3100 Genetic 
Beebe-Dimmer et al. Page 3













Analyzer. Cycle sequencing was accomplished using Big Dye Terminator v3.1 chemistries 
(Applied Biosystems, Foster City, CA).
Our initial analysis indicated that rs12733285 did not achieve Hardy-Weinberg Equilibrium 
(HWE) in controls with an excess of homozygotes for this SNP. We selected a subset of 
individuals that were determined to be homozygous according to SDS 2.1 software, and 
performed direct sequencing to investigate the deviation. Upon sequencing, we discovered 
an additional A→T transversion 1 base-pair before (contig position 53412393) our SNP of 
interest (rs12733285). Due to this observation, we determined that rs12733285 should be 
dropped from our analysis because the additional SNP may change the fidelity of the 
TaqMan probe, thus skewing the accuracy of the genotyping platform and creating the HWE 
deviation. The additional SNP that was observed has not been previously described in the 
dbSNP database and may be segregating preferentially among African Americans.
Statistical Analysis
All statistical analyses were performed using Statistical Analysis Software (SAS Institute 
Inc. v. 9.1, Cary, N.C.). All tests were evaluated using a two-sided hypothesis test with 
statistical significance interpreted as having a p-value less than or equal to 0.05. Obesity was 
defined according to the current Centers for Disease Control (CDC) criteria (≥ 30.0 kg/m2). 
Differences in age and obesity between prostate cancer cases and controls were tested using 
a Wilcoxon rank-sum test and chi-square test, respectively. Differences in the minor allele 
frequency (MAF) in these SNPs between FMHS controls and African American (when 
available) or African samples identified using NCBI's dbSNP database http://
www.ncbi.nlm.nih.gov/projects/SNP/ were tested using chi-square tests. For each SNP, the 
observed genotype distribution among controls was tested for consistency with HWE 
expectations using Pearson's chi-square test. Unconditional logistic regression was used to 
determine whether genotypes within each SNP were associated with either prostate cancer 
or obesity (among controls), with additive, dominant and recessive models A post-hoc test 
comparing homozygotes for the minor allele and heterozygotes each to homozygotes for the 
major allele (the referent) was also performed. All single SNP models were run controlling 
for age and the estimated proportion of African ancestry for each study participant using the 
statistical software Structure(20). Multivariable models simultaneously adjusted for the 
effect of each SNP, including only SNPs within the same gene, age and ancestry. However, 
as adjustment for ancestry did not alter the calculated odds ratios, we report those adjusted 
only for age and other SNPs.
Adiponectin signaling status was assessed using the genotypes at two SNPs (rs1501299 and 
rs2241766) based on their suspected function in regulating circulating adiponectin 
concentrations(18). As such, we attempted to replicate prior findings, classifying subjects 
with the following genotype combinations as low signalers (276*GG/45*TT; 276*GT/
45*TT; 276*GG/45*GT) and intermediate to high signalers with genotype combinations 
(276*TT/45*TT; 276*GT/45*GT; 276*GG/45*GG; 276*GT/45*GG; 276*TT/45*GG; 
276*TT/45*GT) and then comparing the prevalence of these combinations between prostate 
cancer cases and controls.
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A number of key characteristics of FMHS participants related to the current investigation are 
reported in Table 1. The average age among the 475 African American participants 
genotyped for this study was 63.4 years (standard deviation (SD) of 10.0 years). The 
controls were significantly younger with a mean age of 62 years (SD=10.1) compared to 67 
years (SD=8.6) among cases (p<0.0001). Approximately 32% of participants were 
considered obese, with no significant difference in the prevalence of obesity between cases 
(33%) and controls (31%). The absence of any significant association between obesity and 
diabetes with prostate cancer in this population has been reported previously(21). We found 
no difference in the mean proportion of African ancestry between FMHS cases and controls 
(∼71%) as has also been reported (22). The median pre-diagnostic PSA level among cases 
was 6.2 ng/ml [interquartile range (IQR) 4.3-11.9 ng/ml]. Approximately, half of FMHS 
cases were treated surgically (48.1%) and 11% were diagnosed with high grade disease 
(Gleason sum 8-10).
Genotype distributions for nine of ten SNPs were consistent with HWE (p≥0.05). The 
position of each SNP and minor allele frequency (MAF) among FMHS controls were 
reported and this MAF was compared to African American samples identified through the 
NCBI dbSNP database (Table 2). As expected, there were few differences in the MAF 
between groups. The MAF in rs10920531 was significantly higher in FMHS controls 
compared to the HapMap(23) Yoruba (YRI) population (p=0.002), used for comparison as 
data from an African American sample was unavailable in the NCBI database.
We found no significant differences in genotype frequency between prostate cancer cases 
and controls (Table 3). Furthermore, an analysis stratified by body mass index (<30 kg/m2 
and ≥ 30 kg/m2) did not provide evidence for effect modification of the association between 
SNPs and prostate cancer by obesity (data not shown). Likewise, no association was 
observed between adiponectin signaling status and prostate cancer risk. Using genotype data 
from SNPs rs1501299 and rs2241766, the proportion of intermediate to high signalers was 
nearly identical among cases and controls (age-adjusted OR = 0.99; 95% CI = 0.57, 1.73).
Among FMHS controls, two SNPs in ADIPOQ (rs1501299 and rs822395) were significantly 
associated with obesity after adjustment for age (p=0.03 and p=0.04, respectively using an 
additive model) (Table 4). Homozygous subjects for the minor (T) allele in rs1501299 had 
more than twice the odds of obesity (OR = 2.29, 95% CI = 1.12-4.72) compared to 
homozygous subjects for the G allele. Heterozygotes also had greater odds of being obese 
compared to GG homozygotes, although this finding was not statistically significant 
(OR=1.36, 95% CI = 0.81-2.31). Adjustment for other genotyped SNPs in the ADIPOQ did 
not significantly alter these findings. Alternatively, the homozygotes for the minor (C) allele 
in rs822395 were 50% less likely to be obese (OR=0.51, 95% CI=0.25-1.03). However, the 
association was no longer statistically significant after adjustment for rs1501299 (p=0.21).
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Several variants in adiponectin gene (ADIPOQ) and the adiponectin type I receptor 
(ADIPOR1) have been recently implicated in breast and colorectal carcinogenesis(18;19). 
Specifically adiponectin signaling status, an assignment based on the genotype combinations 
of two SNPs in ADIPOQ, was associated with a 36% to 85% reduction in odds of breast 
cancer for intermediate to high signalers. Furthermore, a single SNP in ADIPOR1 
(rs7539542) was inversely associated with breast cancer (OR=0.57; 95% CI=0.35, 0.94)
(18). The same panel of SNPs were analyzed in relation to colorectal cancer, showing a 
single SNP (rs266729) to be inversely associated (OR = 0.73; 95% CI=0.53, 0.99)(19).
In an attempt to extend these findings to prostate cancer, we genotyped these same SNPs in 
a population-based, case-control study of African American men and found no association 
between any SNP and prostate cancer risk. As a dual aim, we investigated the association 
between these variants and body mass in the controls and observed a single SNP 
(rs1501299) to be significantly associated with obesity after controlling for age and other 
genotyped SNPs within the same gene. Previous studies of the +276 G>T polymorphism 
(rs1501299) suggest that this SNP contributes to variability in circulating adiponectin, 
however, a recent meta-analysis indicated significant heterogeneity amongst studies(11). 
Contrary to the assumptions made by Kaklamani et al as to the role of rs1501299 on 
adiponectin levels, it has been surmised that rs1501299 is in linkage disequilibrium with an 
as of yet unidentified functional variant(11). Several studies have also examined the +276 
G>T polymorphism in relation to insulin resistance, cardiovascular disease and obesity, 
producing mixed results(14;24-26). The inconsistencies may be attributed in part to 
differences in the racial composition of the populations under study and/or the presence of 
co-morbidities.
The current investigation is the first to examine the association between variants in genes 
involved in the adiponectin pathway, prostate cancer risk and obesity in African American 
men. Our results are consistent with two previous reports of obesity-related genes and 
prostate cancer risk in Caucasian men (27;28). Neither investigation reported any significant 
difference in genotype distribution between prostate cancer cases and controls in SNPs in 
ADIPOQ, LEP (leptin), LEPR (leptin receptor), TNFα (tumor necrosis factor α), PPARγ 
(peroxisome-proliferator-activated receptor γ), TCF7L2 (transcription factor 7-like2) and 
IL6 (interleukin 6).
Adiponectin is a 244-amino acid, collagen-like protein present in relatively high 
concentrations in humans, accounting for 0.01% to 0.05% of total plasma protein(29). It is 
the most plentiful of the adipokines, with levels approximately 3 times higher than that of 
leptin, a pro-inflammatory cytokine predominantly functioning in the control of 
appetite(30). Unlike other adipokines, circulating adiponectin is inversely related to body 
mass(31) and has a number of important functions which may influence progression of 
prostate cancer explaining the association between obesity and aggressive prostate 
cancer(9;32). Adiponectin possesses anti-proliferative properties demonstrated not only in 
prostate cancer, but also cancers of the breast, endometrium, liver and lung(33). The 
association between adiponectin and prostate cancer may be explained through its effects on 
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immune response, notably activation of several anti-inflammatory cytokines (IL10, IL1RA 
(IL1 receptor antagonist)) and suppression of NFkB dependent-TNF and IFN-γ production 
amongst other pro-inflammatory cytokines(30). Lastly, adiponectin concentrations have 
been linked to markers of insulin resistance and/or insulin sensitivity(34;35).
While our results do not support a contribution of genetic variability in ADIPOQ and 
ADIPOR1 to prostate cancer risk in African Americans, there are several potential 
explanations for the discrepancy between these findings and those linking risk to 
adiponectin concentrations. Racial differences in the distribution of body fat, and the 
prevalence of specific features of the metabolic syndrome (hypertension, diabetes, 
hypertriglyceridemia, low HDL-cholesterol, abdominal obesity) have been well 
documented(36). The relationship between measures of body mass and adiposity with 
adiponectin concentrations has not been as thoroughly studied in African Americans as has 
been in Caucasians, particularly among men, leaving open the possibility of racial 
differences in the role of adiponectin and the initiation, promotion and progression of certain 
cancers. Studies have already demonstrated clear racial differences in the relationship 
between serum adiponectin and coronary heart disease risk(37). Furthermore, there has been 
some demonstration of racial heterogeneity in the contribution of genetics to circulating 
adiponectin levels (38) and insulin resistance (39;40). In a recent investigation, Wassel et al. 
observed that SNPs in ADIPOQ were strongly associated with serum adiponectin in whites, 
but not blacks participating in the Coronary Artery Development in Young Adults 
(CARDIA) study (41).
There are a few limitations which require consideration in the interpretation of our findings. 
First, the study was of limited power to detect modest differences between genotype and 
prostate cancer particularly when the “at-risk” allele frequency was less common in the 
control population. For example, with our sample size of 475 men, we were adequately 
powered (>80%) to detect a minimum two-fold increase in risk with a genotype frequency 
of 20% among controls (α=0.05). Furthermore, the strategy employed by Kaklamani et al to 
preferentially select those SNPs thought to be functionally relevant from a pool of SNPs 
tagging the two major haplotypes blocks within each gene among Caucasians may not 
capture the variation in these genes among African Americans. It is also possible that there 
are additional genes working in concert with the adiponectin genes which would need to be 
included to observe an effect on prostate cancer risk and clearly, testing for gene-gene 
interaction would necessitate a larger sample size. Despite these limitations, the Flint Men's 
Health Study remains one of the largest population-based investigations of prostate cancer 
conducted exclusively in an African American population. The comprehensive collection of 
clinical, epidemiologic and anthropometric measures, as well as the careful screening and 
follow-up of the control population are among the numerous strengths of the study design.
The results of the current investigation suggest that variation in the adiponectin gene 
associates with obesity, but is unrelated to prostate cancer risk in African American men. 
These findings suggest that the underlying biology of adiposity and prostate cancer is a 
complicated one and we still have much to discover about the factors which mediate this 
relationship. Further study, particularly among African Americans, is clearly justified given 
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the racial disparity in incidence of disease and outcomes post-diagnosis coupled with the 
epidemic increase in obesity in the U.S. across racial groups over the past few decades.
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Table 1
Baseline characteristics of 475* African American men participating in the FMHS. [Mean (SD) or (%)]





Age (years) 67.2 (8.6) 62.1 (10.1) <0.0001
BMI (%)
 <25 kg/m2 24.8 33.4
 25-29.9 kg/m2 41.9 35.8
 ≥ 30 kg/m2 33.3 30.8 0.18
Diabetes (%) 22.0 18.1 0.35
Family History (%) 21.4 17.0 0.17
% African Ancestry 70.4 (0.08) 70.6 (0.08) 0.78
*
Results exclude missing data
‡
Associated with either Chi-square or Wilcoxon test statistic
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Table 2
Single Nucleotide Polymorphisms in the Adiponectin (ADIPOQ) and Adiponectin Receptor (ADIPOR1) in the 
Flint Men's Health Study.
Position Gene MAF (%) NCBI dbSNP† MAF (%)* FMHS p-value
-11365 C>G ADIPOQ 18.2a 11.1 0.16
-4034 A>C ADIPOQ 41.3a 44.5 0.64
-3964 A>G ADIPOQ 20.0b 20.3 0.93
+45 T>G ADIPOQ 4.1c 4.7 0.72
+276 G>T ADIPOQ 27.1d 35.6 0.05
-11760 G>A ADIPOR1 10.9a 11.7 0.94
+5843 C>T ADIPOR1 43.5a 48.0 0.53
+10225 G>C ADIPOR1 NA 35.9 --




Minor allele frequencies based on African or African American (AA) samples from:
a
Perlegen AFD_AFR panel AA samples selected from the human variation panel of 50 African Americans (HD50AA-Coriell Cell Repository).
b
International HapMap project samples Yorubian (YRI) population from Nigeria.
c
Perlegen (P3) AA control samples from the Human Diversity Panel.
d
SNP500panel (P1) anonymized samples with self-identified race as AA.
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